A randomized controlled trial of adjunctive iTBS targeting the dorsomedial prefrontal cortex for anhedonia in schizophrenia: rationale and protocol design
If the iTBS protocols targeting the DMPFC lead to positive changes in anhedonia symptoms in patients with schizophrenia, this would provide a new intervention strategy for negative symptoms. Furthermore, leveraging neuroimaging evidence from such studies could help optimize rTMS target selection and overall treatment strategies.Trial registration: ChiCTR2500107965.
Authors
- Kezhi Liu (ORCID: https://orcid.org/0000-0003-4515-4209)
- Long Yun (ORCID: https://orcid.org/0000-0001-7304-1231)
- Youguo Tan (ORCID: https://orcid.org/0000-0002-4892-3758)
- Yuke He (ORCID: https://orcid.org/0000-0002-6716-198X)
- Bo Liu (ORCID: https://orcid.org/0000-0002-3482-6930)
- W. Xu (ORCID: https://orcid.org/0000-0002-0040-0616)
- Wenzhong Liu (ORCID: https://orcid.org/0000-0003-0474-0770)
- Mei Yu
- Hao Wu (ORCID: https://orcid.org/0009-0000-1496-5290)
- H Den
- Fan Yang (ORCID: https://orcid.org/0000-0002-8111-4880)
Institutions
- Affiliated Hospital of Southwest Medical University (CN)
- Zigong Light Industry Design Institute (China) (CN)
- Zigong First People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Psychiatry
- Published
- 2025-11-24
- DOI
- https://doi.org/10.3389/fpsyt.2025.1706553
- Primary Topic
- Neurotransmitter Receptor Influence on Behavior
- Type
- article
- Field-Weighted Citation Impact
- 0.00